Should You Buy Compugen Ltd. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Compugen Ltd. (CGEN) is rated as a strong fundamental performer with a QOC score of 9.0/10. Trading at $2.41, our valuation engine evaluates whether the market price reflects the company's underlying earnings power.
The short answer: 3 of 9 CirclFi valuation models project upside for Compugen Ltd. (CGEN) at $2.41 — the model consensus leans bearish, with a Quality Score of 9.0/10 and Value-Trap risk of 18/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for Compugen Ltd. (CGEN) in 2026?
What Is the Bull Case vs the Bear Case for Compugen Ltd. (CGEN)?
| Bull case — $2.87 target (+19.1%) | Bear case — $1.36 target (-43.5%) |
|---|---|
| According to the CirclFi Quality of Company (QOC) framework, Compugen Ltd.'s rating of 9.0/10 signals strong fundamentals — high-quality businesses tend to compound value more reliably. | According to the CirclFi Deep Alpha Valuation Engine, the ML Residual Income model sees the stock as overvalued with a fair value of $1.36 (-43.5%), suggesting that the market price embeds overly optimistic growth assumptions. |
| According to the CirclFi Deep Alpha Valuation Engine, the EROIC Spread model targets a fair value of $2.87 (+19.1%), anchoring the bull case with a methodology that provides a differentiated analytical lens. | According to the CirclFi Deep Alpha Valuation Engine, model disagreement is high with a +62.6% spread between the most bullish and bearish models, signaling elevated analytical uncertainty. |
| Industry tailwind: first-mover advantage in novel targets could provide meaningful support for Compugen Ltd.'s revenue and margin trajectory in the Biotechnology space. | Industry headwind: competitive pipeline overlap represents a meaningful risk for Compugen Ltd. and its Biotechnology peers. |
How Does CGEN Compare to Its Biotechnology Peers?
Valuation data pages: CRMD · VCEL · ONC · PTCT · VRTX · PBYI · NKTR · DRUG · JBIO · EXEL · INCY
Which Other Stocks Score Like CGEN on Quality?
Closest companies to CGEN’s Quality of Company score of 9.0/10, across all industries.
- BFST — Business First Bancshares, Inc. (QOC 9.0) · analysis
- IMAX — IMAX Corporation (QOC 9.0) · analysis
- DRD — DRDGOLD Limited (QOC 9.0) · analysis
- JBL — Jabil Inc. (QOC 9.0) · analysis
- TPR — Tapestry, Inc. (QOC 9.0) · analysis
- RPM — RPM International Inc. (QOC 9.0) · analysis
- NVDA — NVIDIA Corporation (QOC 10.0) · analysis
Which Biotechnology Screens Does CGEN Appear In?
So Is Compugen Ltd. (CGEN) Worth Buying in 2026?
Caution dominates our read on Compugen Ltd. at $2.41. 6 of 9 models see limited upside or outright downside, with the median fair value at $2.03 (-15.9%). Quality at 9.0/10 provides some fundamental cushion. Current holders should re-evaluate their thesis; new buyers should demand a wider margin of safety.
These are quantitative model outputs, not investment recommendations. Compugen Ltd.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About CGEN Stock?
Should I buy CGEN stock right now?
Based on CirclFi's multi-model analysis, 3 of 9 models see upside for CGEN at $2.41. The models are divided, which means the investment case depends heavily on your assumptions about Compugen Ltd.'s future. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Compugen Ltd.?
Key risks include: wide model disagreement (111% spread), signaling high uncertainty; general market and sector-specific risks affecting Biotechnology companies. Always diversify and consult a financial advisor.
How does CGEN compare to its competitors?
Among Biotechnology peers, CGEN holds a Quality Score of 9.0/10. Comparable companies include CRMD (QOC 9.0), VCEL (QOC 8.8), ONC (QOC 9.0). The relative ranking helps investors identify whether CGEN offers better fundamental quality than alternatives in the same sector.
Is CGEN a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. CGEN's Quality Score of 9.0/10 is encouraging for long-term holders, indicating consistent profitability, manageable debt, and healthy cash flows. Check our full data page for all 13 model estimates.
What price should I buy CGEN at?
CirclFi does not provide target buy prices or price alerts. However, our 9 active models produce fair value estimates ranging from $1.36 to $2.87. At $2.41, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for CGEN.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad